ArticleCancer science2021

MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.

Reheman Yiming et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.